CGBIO Receives FDA 510(k) Clearance for EASYMADE TI Patient-Specific Titanium Implant

Key Takeaways

• CGBIO becomes the first Korean company to receive FDA 510(k) clearance for a customized titanium implant in the U.S. market
• EASYMADE TI patient-specific titanium implant received FDA clearance on April 9, 2026, enabling U.S. commercialization
• The 510(k) clearance demonstrates substantial equivalence to existing predicate devices, paving the way for market entry

---

CGBIO announced that its patient-specific titanium implant EASYMADE TI has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) on April 9, 2026. The South Korean medical device company, led by CEO Hyunseung Yu, becomes the first Korean firm to obtain FDA clearance for a customized titanium implant in the U.S. market.

Regulatory Milestone for Korean Medical Device Industry

The FDA 510(k) pathway is a premarket clearance process that demonstrates substantial equivalence to a legally marketed predicate device. This clearance allows CGBIO to commercialize EASYMADE TI in the United States, representing a significant regulatory achievement for the company and the broader Korean medical device sector.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Patient-Specific Implant Technology

EASYMADE TI represents advanced personalized medicine in orthopedic care, offering patient-specific titanium implants tailored to individual anatomical requirements. This customization approach can potentially improve surgical outcomes and patient recovery times compared to standard, one-size-fits-all implant solutions.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Market Impact and Commercial Implications

The FDA clearance opens access to the substantial U.S. orthopedic implant market for CGBIO. Patient-specific implants represent a growing segment within the broader orthopedic device market, driven by advances in 3D printing technology and personalized medicine approaches.

This regulatory success positions CGBIO to compete with established medical device manufacturers in the premium segment of orthopedic implants. The company can now pursue commercial partnerships and direct sales in the U.S. healthcare system.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for pharmaceutical intelligence pricing, access, and launch sequencing.

Next Steps for CGBIO

With FDA clearance secured, CGBIO will likely focus on establishing distribution networks, training healthcare providers on the EASYMADE TI system, and building market awareness among orthopedic surgeons. The company may also leverage this regulatory success to pursue additional clearances for related products or expand into other international markets.

---

Frequently Asked Questions

What does FDA 510(k) clearance mean for EASYMADE TI?

FDA 510(k) clearance means EASYMADE TI has been deemed substantially equivalent to existing approved devices and can be legally marketed and sold in the United States.

When will EASYMADE TI be available to patients in the U.S.?

With FDA clearance received on April 9, 2026, CGBIO can now begin commercialization, though specific availability will depend on the company’s distribution and market launch timeline.

How do patient-specific titanium implants differ from standard implants?

Patient-specific implants like EASYMADE TI are custom-designed based on individual patient anatomy, potentially offering better fit, improved surgical outcomes, and faster recovery compared to standard implants.

Related coverage

• BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial